Skip to NavigationSkip to content

Pharmafile - Sales and Marketing News

AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry...
Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will cost $88,000 a...
Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type 1 diabetes in combination with...
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous...
Africa’s legal cannabis market could generate more than $7.1 billion each year by 2023, according to a report from market intelligence firm...
AstraZeneca's Forxiga has secured approval from the European Commission for the treatment of type 1 diabetes – the first approval for the drug in...
The Advertising Standards Authority (ASA) has told British therapists to stop marketing a sham ‘cure’ for autism.
Jazz Pharmaceuticals has announced that its dopamine and norepinephrine reuptake inhibitor (DNRI) Sunosi (solriamfetol) has been approved by the...
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on hold after a number of patient deaths...
Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug in combination...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches